RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $50 to $42.
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $50 to $42.